Information Provided By: 
Fly News Breaks for November 1, 2018
HZNP
Nov 1, 2018 | 08:03 EDT
After hosting a call with a leading oculoplastic surgeon, Stifel analyst Annabel Samimy said she gained further confidence in her view that teprotumumab will have clinical success in Phase 3 and, more importantly, commercial success. Assuming a "high probability of success" of about 85% for teprotumumab, she raised her price target for Horizon Pharma shares to $35 from $25 and keeps a Buy rating on the stock.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
